Key facts
- This page summarizes Daniel Janney's Form 4 filing for Krystal Biotech, Inc. (KRYS).
- 22 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 26 Feb 2026, 18:49.
Daniel Janney - 24 Feb 2026 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)
- Reporting relationship
- Director
- Issuer ticker
- KRYS
- Reported as of
- 24 Feb 2026
- Net transaction value
- -$16,056,161
- SEC form
- 4
- Accepted by SEC
- 26 Feb 2026, 18:49:48 UTC
- Prior SEC filing
- 30 Jun 2025
- Next SEC filing
- 03 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Krish Krishnan, as attorney-in-fact for Daniel Janney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel Janney filed Form 4 for Krystal Biotech, Inc. (KRYS) on 26 Feb 2026.
Change
- Previous filing in this sequence was filed on 30 Jun 2025.
- Current net transaction value: -$16,056,161.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001198325
Primary reporting owner
JANNEY DANIEL
- Relationship
- Director
- Address
- C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH
- Signature
- /s/ Krish Krishnan, as attorney-in-fact for Daniel Janney
- Signature date
- 26 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KRYS
transaction
Common Stock
Options Exercise
- Transaction value
- $93,222
- Shares
- +37,895
- Change %
- Price
- $2.46
- Shares after
- 37,895
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
KRYS
transaction
Common Stock
Sale
- Transaction value
- $149,594
- Shares
- -569
- Change %
- -1.5%
- Price
- $262.91
- Shares after
- 37,326
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F2
KRYS
transaction
Common Stock
Sale
- Transaction value
- $457,728
- Shares
- -1,733
- Change %
- -4.6%
- Price
- $264.12
- Shares after
- 35,593
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F3
KRYS
transaction
Common Stock
Sale
- Transaction value
- $942,878
- Shares
- -3,557
- Change %
- -10%
- Price
- $265.08
- Shares after
- 32,036
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F4
KRYS
transaction
Common Stock
Sale
- Transaction value
- $2,391,885
- Shares
- -8,986
- Change %
- -28%
- Price
- $266.18
- Shares after
- 23,050
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F5
KRYS
transaction
Common Stock
Sale
- Transaction value
- $3,116,310
- Shares
- -11,673
- Change %
- -51%
- Price
- $266.97
- Shares after
- 11,377
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F6
KRYS
transaction
Common Stock
Sale
- Transaction value
- $1,788,079
- Shares
- -6,671
- Change %
- -59%
- Price
- $268.04
- Shares after
- 4,706
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F7
KRYS
transaction
Common Stock
Sale
- Transaction value
- $1,065,924
- Shares
- -3,963
- Change %
- -84%
- Price
- $268.97
- Shares after
- 743
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F8
KRYS
transaction
Common Stock
Sale
- Transaction value
- $99,836
- Shares
- -370
- Change %
- -50%
- Price
- $269.83
- Shares after
- 373
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F9
KRYS
transaction
Common Stock
Sale
- Transaction value
- $101,118
- Shares
- -373
- Change %
- -100%
- Price
- $271.09
- Shares after
- 0
- Date
- 24 Feb 2026
- Ownership
- Direct
- Footnotes
- F10
KRYS
transaction
Common Stock
Sale
- Transaction value
- $16,309
- Shares
- -62
- Change %
- -0.06%
- Price
- $263.05
- Shares after
- 107,300
- Date
- 24 Feb 2026
- Ownership
- Directly beneficially owned by Alta Bioequities, L.P.
- Footnotes
- F11, F12, F13
KRYS
transaction
Common Stock
Sale
- Transaction value
- $238,136
- Shares
- -900
- Change %
- -0.84%
- Price
- $264.60
- Shares after
- 106,400
- Date
- 24 Feb 2026
- Ownership
- Directly beneficially owned by Alta Bioequities, L.P.
- Footnotes
- F11, F13, F14
KRYS
transaction
Common Stock
Sale
- Transaction value
- $425,919
- Shares
- -1,604
- Change %
- -1.5%
- Price
- $265.54
- Shares after
- 104,796
- Date
- 24 Feb 2026
- Ownership
- Directly beneficially owned by Alta Bioequities, L.P.
- Footnotes
- F11, F13, F15
KRYS
transaction
Common Stock
Sale
- Transaction value
- $1,156,879
- Shares
- -4,339
- Change %
- -4.1%
- Price
- $266.62
- Shares after
- 100,457
- Date
- 24 Feb 2026
- Ownership
- Directly beneficially owned by Alta Bioequities, L.P.
- Footnotes
- F11, F13, F16
KRYS
transaction
Common Stock
Sale
- Transaction value
- $505,597
- Shares
- -1,891
- Change %
- -1.9%
- Price
- $267.37
- Shares after
- 98,566
- Date
- 24 Feb 2026
- Ownership
- Directly beneficially owned by Alta Bioequities, L.P.
- Footnotes
- F11, F13, F17
KRYS
transaction
Common Stock
Sale
- Transaction value
- $449,747
- Shares
- -1,674
- Change %
- -1.7%
- Price
- $268.67
- Shares after
- 96,892
- Date
- 24 Feb 2026
- Ownership
- Directly beneficially owned by Alta Bioequities, L.P.
- Footnotes
- F11, F13, F18
KRYS
transaction
Common Stock
Sale
- Transaction value
- $250,636
- Shares
- -930
- Change %
- -0.96%
- Price
- $269.50
- Shares after
- 95,962
- Date
- 24 Feb 2026
- Ownership
- Directly beneficially owned by Alta Bioequities, L.P.
- Footnotes
- F11, F13, F19
KRYS
transaction
Common Stock
Sale
- Transaction value
- $666,627
- Shares
- -2,425
- Change %
- -2.5%
- Price
- $274.90
- Shares after
- 93,537
- Date
- 24 Feb 2026
- Ownership
- Directly beneficially owned by Alta Bioequities, L.P.
- Footnotes
- F11, F13, F20
KRYS
transaction
Common Stock
Sale
- Transaction value
- $192,500
- Shares
- -700
- Change %
- -0.75%
- Price
- $275.00
- Shares after
- 92,837
- Date
- 25 Feb 2026
- Ownership
- Directly beneficially owned by Alta Bioequities, L.P.
- Footnotes
- F11, F13, F21
KRYS
transaction
Common Stock
Sale
- Transaction value
- $1,404,760
- Shares
- -5,103
- Change %
- -5.5%
- Price
- $275.28
- Shares after
- 87,734
- Date
- 26 Feb 2026
- Ownership
- Directly beneficially owned by Alta Bioequities, L.P.
- Footnotes
- F11, F13, F22
KRYS
transaction
Common Stock
Sale
- Transaction value
- $728,919
- Shares
- -2,638
- Change %
- -3%
- Price
- $276.32
- Shares after
- 85,096
- Date
- 26 Feb 2026
- Ownership
- Directly beneficially owned by Alta Bioequities, L.P.
- Footnotes
- F11, F13, F23
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KRYS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -37,895
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 24 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,895
- Exercise price
- $2.46
- Footnotes
- F1, F24
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 24 footnotes
Footnote F1
The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.
Footnote F2
The transaction was executed in multiple trades ranging from $262.480 to $263.400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F3
The transaction was executed in multiple trades ranging from $263.510 to $264.450. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F4
The transaction was executed in multiple trades ranging from $264.520 to $265.495. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F5
The transaction was executed in multiple trades ranging from $265.520 to $266.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F6
The transaction was executed in multiple trades ranging from $266.520 to $267.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F7
The transaction was executed in multiple trades ranging from $267.520 to $268.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F8
The transaction was executed in multiple trades ranging from $268.540 to $269.530. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F9
The transaction was executed in multiple trades ranging from $269.610 to $270.140. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F10
The transaction was executed in multiple trades ranging from $270.650 to $271.610. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F11
The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.
Footnote F12
The transaction was executed in multiple trades ranging from $262.9496 to $263.1269. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F13
Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Footnote F14
The transaction was executed in multiple trades ranging from $264.01 to $264.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F15
The transaction was executed in multiple trades ranging from $265.04 to $266. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F16
The transaction was executed in multiple trades ranging from $266.06 to $267.0511. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F17
The transaction was executed in multiple trades ranging from $267.0631 to $268.0275. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F18
The transaction was executed in multiple trades ranging from $268.0725 to $269.0705. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F19
The transaction was executed in multiple trades ranging from $269.1641 to $269.78. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F20
The transaction was executed in multiple trades ranging from $274.59 to $275. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F21
The transaction was executed in a single trade.
Footnote F22
The transaction was executed in multiple trades ranging from $275 to $275.9782. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F23
The transaction was executed in multiple trades ranging from $276 to $276.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F24
The options vested ratably over a four-year period beginning on November 10, 2016.